Pediatrix director disposes 18,500 shares at $26.62

Pediatrix Medical Group, Inc. (MD) director Sylvia Jean Young reported a disposition of common stock to the issuer.

Rhea-AI Filing Summary

Pediatrix Medical Group, Inc. (MD) director Sylvia Jean Young reported a disposition of common stock to the issuer. On 2026-08-14, she disposed of 18,500 shares at a weighted average price of $26.62 per share, in multiple transactions executed between $26.51 and $26.80. Following this issuer disposition, she directly holds 29,786 shares of Pediatrix Medical Group common stock.

Insider Trade Summary

Disposition: 18,500 shares

Disposition 1 txn

Insider Young Sylvia Jean

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock F1	18,500	$26.62	$492K

Holdings After Transaction: Common Stock — 29,786 shares (Direct)

Footnotes (1)

1. F1. The price in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.51 to $26.80 for a weighted average sales price of $26.62. The reporting person undertakes to provide the issuer, any security holder of the issuer of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares disposed: 18,500 shares Weighted average price: $26.62 per share Price range: $26.51–$26.80 per share +1 more

4 metrics

Shares disposed 18,500 shares Common stock disposition to issuer on 2026-08-14

Weighted average price $26.62 per share Weighted average sales price for the 18,500-share disposition

Price range $26.51–$26.80 per share Range of prices for multiple transactions included in the disposition

Shares owned after transaction 29,786 shares Direct holdings of Sylvia Jean Young after the reported disposition

Key Terms

Disposition to issuer, weighted average price, beneficial owner

3 terms

Disposition to issuer financial

"The transaction is coded D, described as a Disposition to issuer"

weighted average price financial

"The price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial owner financial

"any security holder of the issuer of the Securities and Exchange Commission upon request"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MD director Sylvia Jean Young report?

Sylvia Jean Young reported a disposition of 18,500 MD shares to Pediatrix Medical Group on 2026-08-14 at a weighted average price of $26.62 per share, leaving her with 29,786 shares held directly.

At what prices were Pediatrix Medical Group (MD) shares disposed of in this Form 4?

The reported 18,500 MD shares were disposed of in multiple transactions with prices ranging from $26.51 to $26.80, resulting in a weighted average sales price of $26.62 per share, as disclosed in the transaction footnote.

How many Pediatrix Medical Group (MD) shares does Sylvia Jean Young own after the transaction?

After the reported disposition, Sylvia Jean Young directly owns 29,786 shares of Pediatrix Medical Group common stock, according to the post-transaction holdings figure disclosed in the Form 4.

Was the MD insider transaction reported under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not affirmed (set to false), and no footnote indicates a trading plan, so the reported 18,500-share disposition is not disclosed as occurring under a Rule 10b5-1 plan.

What type of transaction code was used in this Pediatrix Medical Group (MD) Form 4?

The transaction is coded D, described as a Disposition to issuer. It reflects 18,500 MD common shares disposed of back to Pediatrix Medical Group, rather than an open-market purchase or sale coded P or S.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:01 PM EDT Accepted by SEC EDGAR 08/18/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Sylvia Jean

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		D		18,500	D	$26.62(1)	29,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.51 to $26.80 for a weighted average sales price of $26.62. The reporting person undertakes to provide the issuer, any security holder of the issuer of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ David Haddock, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)